Annals of Thoracic Medicine
CASE REPORT
Year
: 2017  |  Volume : 12  |  Issue : 1  |  Page : 57--58

Herceptin responsive lung adenocarcinoma in the setting of bilateral synchronous lung primaries and breast carcinoma


Gerard J Fitzmaurice, Michael Moore, Waris Ahmad, Ronan J Ryan 
 Department of Cardiothoracic Surgery, St. James's Hospital, Dublin, Ireland

Correspondence Address:
Gerard J Fitzmaurice
Department of Cardiothoracic Surgery, St. James«SQ»s Hospital, Dublin
Ireland

The incidence of human epidermal growth factor receptor 2 (Her-2) mutations in lung adenocarcinoma is approximately 3%; however, its significance in the management of these lung cancers remains under investigation. We describe an incidental but unique opportunity to evaluate the response to treatment with herceptin in a patient with bilateral synchronous lung primaries in conjunction with breast carcinoma. Interval imaging following surgical resection of the squamous cell carcinoma while on herceptin treatment delineated the radiological regression of the Her-2 positive lung adenocarcinoma. We feel that this case highlights the potential role for herceptin treatment in Her-2 positive lung adenocarcinomas and demonstrates the importance of screening for these mutations.


How to cite this article:
Fitzmaurice GJ, Moore M, Ahmad W, Ryan RJ. Herceptin responsive lung adenocarcinoma in the setting of bilateral synchronous lung primaries and breast carcinoma.Ann Thorac Med 2017;12:57-58


How to cite this URL:
Fitzmaurice GJ, Moore M, Ahmad W, Ryan RJ. Herceptin responsive lung adenocarcinoma in the setting of bilateral synchronous lung primaries and breast carcinoma. Ann Thorac Med [serial online] 2017 [cited 2020 Jul 13 ];12:57-58
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2017;volume=12;issue=1;spage=57;epage=58;aulast=Fitzmaurice;type=0